Pathophysiology

Hyperbaric Oxygen Therapy Shows Promise in Addressing Long COVID Pathophysiology, According to Clinical Review Authored by Hyperbaric Medical Solutions Directors

Retrieved on: 
목요일, 2월 22, 2024
Regenerative medicine, MD, Quality of life, Safety, Medicine, Pathophysiology, Deficit spending, Fatigue, Patient, COVID, HBOT, Frontiers in Medicine, Research, Pharmaceutical industry

WOODBURY, N.Y., Feb. 22, 2024 /PRNewswire-PRWeb/ -- A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID. The study, titled "Hyperbaric Oxygen Effectively Addresses the Pathophysiology of Long COVID: Clinical Review," was authored by the National Medical Director, and the New England Clinical Director of Hyperbaric Medical Solutions, alongside three other esteemed researchers.

Key Points: 
  • A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID.
  • WOODBURY, N.Y., Feb. 22, 2024 /PRNewswire-PRWeb/ -- A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID.
  • The study, titled "Hyperbaric Oxygen Effectively Addresses the Pathophysiology of Long COVID: Clinical Review," was authored by the National Medical Director, and the New England Clinical Director of Hyperbaric Medical Solutions, alongside three other esteemed researchers.
  • Hyperbaric Medical Solutions , a leading provider of hyperbaric oxygen therapy, has been at the forefront of treating long COVID patients with positive outcomes.

New Research Uncovers Vascular Benefits of Peanut Consumption on Young Adults

Retrieved on: 
수요일, 4월 19, 2023
Cognition, Pathophysiology, Heart, Faculty, Pinterest, Consumer, Mineral, Obesity, University, Food science, Nut, Nutrition, Heart failure, Diabetes, Food industry, INSA, Endocarditis, Molina Healthcare, Cardiovascular disease, University of Barcelona, Research, Multimedia, Inflammation, Atherosclerosis, Vitamin, Incidence, Polyphenol, Antioxidant, Risk, Sterling, Peanut, Mental health, Memory, News, JAMA, Dietary supplement, Pharmacy

The research, which was recently published in the journal Antioxidants and shared by The Peanut Institute , discusses a preventive medicine approach for younger generations.

Key Points: 
  • The research, which was recently published in the journal Antioxidants and shared by The Peanut Institute , discusses a preventive medicine approach for younger generations.
  • The six-month study conducted by the University of Barcelona involved 63 healthy young adults ages 18-33 who included a single serving of peanuts or peanut butter in their regular, daily diet.
  • "There's an urgent need to focus cardiovascular disease education and prevention efforts on young adults," says Dr. Sterling.
  • "Urinary Phenolic Metabolites Associated with Peanut Consumption May Have a Beneficial Impact on Vascular Health Biomarkers ".

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Retrieved on: 
수요일, 2월 1, 2023
Pulmonary hypertension, National Science Advisory Board for Biosecurity, Human, IV, Intellectual property, United States Patent and Trademark Office, American Heart Association, IP, Pathophysiology, Heart failure, Patient, Patent, Levosimendan, HELP, FDA, Mortality, 1836 U.S. Patent Office fire, Randomized controlled trial, Therapy, Pharmaceutical industry

This Notice of Allowance further builds upon the Company’s significant IP for levosimendan, which includes U.S. Patent No.

Key Points: 
  • This Notice of Allowance further builds upon the Company’s significant IP for levosimendan, which includes U.S. Patent No.
  • 11,213,524 that was issued in January 2022 and covers all medical uses in humans of the subcutaneous formulation of levosimendan.
  • When transitioning to the oral daily formulation after a lengthy treatment with the weekly IV formulation, the 6-minute walk results improved further.
  • "Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association."

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

Retrieved on: 
목요일, 12월 15, 2022
Eye, CST, Patient, Inflammation, Disulfiram-like drug, PKI, MAD, Severe cognitive impairment, Safety, Diabetic retinopathy, Retina, Pharmacokinetics, DR, DME, World Diabetes Day, Diabetes, SAD, Visual acuity, Risk, Bradykinin, Kallikrein, Pathophysiology, HIV disease progression rates, Injection, Congenital hyperinsulinism, Pharmaceutical industry, Rezolution Pictures, Snellen

The invasive route of administration, coupled with inadequate responsiveness in some patients, leads to overall undertreatment and suboptimal vision outcomes in DME patients.

Key Points: 
  • The invasive route of administration, coupled with inadequate responsiveness in some patients, leads to overall undertreatment and suboptimal vision outcomes in DME patients.
  • Patients who have previously received more than three anti-VEGF injections prior to the study will be excluded.
  • The study is expected to enroll approximately 100 patients overall, across approximately 25 investigational sites in the United States.
  • Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema.

Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury

Retrieved on: 
목요일, 6월 9, 2022
Professional Services, Health, Other Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, ADR, Bont, SCI, Powder, Research, III, Medicine, Product, Medication package insert, Patent, Ipsen, Epidemiology, Torticollis, NDO, CIC, IPN, MS, Face, Risk, Safety, Social isolation, Quality of life, UI, Union, Clinical trial, Neurogenic bladder dysfunction, Catheter, Toxin (comics), Heart, European Urology, Pathophysiology, Birth control, Pharmaceutical industry, Euronext, Botulinum toxin, Botulinum toxin, Neuroscience, Patient

In addition, Ipsen is also currently in the process of obtaining approvals in other countries outside the European Union.

Key Points: 
  • In addition, Ipsen is also currently in the process of obtaining approvals in other countries outside the European Union.
  • Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience.
  • The forward-looking statements, objectives and targets contained herein are based on Ipsens management strategy, current views and assumptions.
  • Evaluation, treatment, and surveillance of neurogenic detrusor overactivity in spinal cord injury patients.

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Retrieved on: 
화요일, 2월 22, 2022
Eye, GLOBE, Congenital hyperinsulinism, Bradykinin, Compliance, HIV disease progression rates, SAD, DR, CHI, Twitter, Index (publishing), Securities Exchange Act of 1934, Diabetes, Pharmacokinetics, Inflammation, Retina, Diabetic retinopathy, Severe cognitive impairment, Company, Volunteering, Injection, Private Securities Litigation Reform Act, Safety, DME, Lists of diseases, Adult, Senior, Rezolution Pictures, Pengkhianatan G30S/PKI, Degenerative disease, Kallikrein, Hereditary angioedema, Securities Act of 1933, Nasdaq, Forward-looking statement, Patient, MAD, Plasma kallikrein, MD, PKI, Plasma, Pathophysiology, Pharmaceutical industry, Risk management

Results of the MAD study further validate and support the potential for once daily oral dosing and enable the company to initiate a Phase 2 proof-of-concept study later this year.

Key Points: 
  • Results of the MAD study further validate and support the potential for once daily oral dosing and enable the company to initiate a Phase 2 proof-of-concept study later this year.
  • By doing so, RZ402 may be able to prevent disease progression and treat vision loss for those suffering with DME, said, Raj Agrawal, MD, Vice President at Rezolute.
  • The MAD study results showed that RZ402 was generally safe and well-tolerated, including at higher doses than previously tested in the SAD study.
  • RZ402 is a selective and potent plasma kallikrein inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of diabetic macular edema (DME).

Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPace™ System

Retrieved on: 
월요일, 2월 14, 2022
Trauma, American Journal, PMID, Physician, Patient, Pathophysiology, AJRCCM, Act, Mitt, EUA, Risk, Health, YouTube, American College, Veni, vidi, vici, GLOBE, Standard of care, Weaning, Technology, Division, LinkedIn, Twitter, PP, Diaphragm, FDA, Stanford University School of Medicine, Publication, Survival, Ochsner, MIP, Professor, Research, Principal investigator, Conference, COVID-19, The New England Journal of Medicine, Exercise, Trial of the century, Federal, RSBI, Medical device, Pharmaceutical industry, Birth control

EXTON, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence.

Key Points: 
  • EXTON, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence.
  • The RESCUE 3 study is the third in a series of studies to support FDA and international regulatory approvals.
  • Once approved, the AeroPace system has the potential to dramatically improve the standard of care and transform the future of ventilation.
  • AeroPace is a great new system, and we look forward to utilizing this technology more in the future.

Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Retrieved on: 
화요일, 8월 10, 2021
Private Securities Litigation Reform Act, Diabetes, Diabetic retinopathy, Patient, Drug, Retina, Eye, Adult, Ophthalmology, Lists of diseases, Program, Kallikrein, Nasdaq, PKI, Safety, Solution, CHI, Rezolution Pictures, Securities Exchange Act of 1934, Pathophysiology, DME, Injection, Compliance, Congenital hyperinsulinism, Twitter, Senior, Drug development, Severe cognitive impairment, Index (publishing), GLOBE, Volunteering, MS, Forward-looking statement, Hereditary angioedema, Â, Bradykinin, Inflammation, Company, Pharmacokinetics, DR, Securities Act of 1933, Pharmaceutical industry, Risk management

I regularly witness the unfortunate impact of retinal diseases on patients, and Rezolutes innovative approach would be a huge step forward for the DME community.

Key Points: 
  • I regularly witness the unfortunate impact of retinal diseases on patients, and Rezolutes innovative approach would be a huge step forward for the DME community.
  • RZ402 is a selective and potent plasma kallikrein inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of diabetic macular edema (DME).
  • Rezolute also presented at the 2021 Stanford Retina Innovation Summit last month discussing RZ402 and targeting DME with kallikrein inhibitors.
  • Within each dose cohort, subjects will be randomized in an 8:2 ratio to receive either RZ402 oral solution or matched placebo.

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery

Retrieved on: 
월요일, 10월 5, 2020
Branches of biology, Biology, Biomarkers, Biotechnology, Chemical pathology, Pathophysiology

The talk entitled, Phase 1b Study inAD Patients withNeuroinflammation, will be given today at 11:20AM ET as part of this years virtual 21st International Conference on Alzheimers Drug Discovery meeting .

Key Points: 
  • The talk entitled, Phase 1b Study inAD Patients withNeuroinflammation, will be given today at 11:20AM ET as part of this years virtual 21st International Conference on Alzheimers Drug Discovery meeting .
  • The trial continues to enroll patients and additional data on the Phase Ib study will be presented in the near future.
  • Neuroinflammation plays an important role in the pathophysiology of Alzheimers disease, said CJ Barnum PhD, Head of Neurosciences at INmune Bio.
  • This Phase Ib multi-center, open label study will enroll patients with biomarkers of inflammation that have Alzheimers disease.

NeurExo Sciences and Henry Ford Health System Announce Upcoming Presentations on Exosomes in Stroke at 45th International Stroke Conference February 6-8

Retrieved on: 
목요일, 1월 31, 2019
Branches of biology, Medical specialties, Medicine, Neurology, Neuroprotection, microRNA, Pathophysiology, Traumatic brain injury, Stroke

The live event is open to institutional/venture investors, sell-side analysts, investment bankers, and business development professionals.

Key Points: 
  • The live event is open to institutional/venture investors, sell-side analysts, investment bankers, and business development professionals.
  • If you are interested in attending, please contact Susan Pietropaolo ( [email protected] ; 201-923-2049) for more information.
  • The focus of the laboratory is the pathophysiology of stroke and traumatic brain injury; mechanisms of neuroprotection, and cell-based, biologic (e.g.
  • NXS has worldwide commercial rights to product candidates resulting from the exosome and miRNA IP and sponsored research generated by the lab.